Collaborative Stage

Note 1:
        A. In cases where ER and PR are reported on more than one tumor specimen, record the highest value (if any sample is positive, record as positive).
        B. If neoadjuvant therapy is given, record the assay from tumor specimens prior to neoadjuvant therapy.
        C. If neoadjuvant therapy is given and there are no ER or PR results from pre-treatment specimens, report the findings from post-treatment specimens.
Note 2: In general, ER/PR is only done on one sample. In cases where it is done on more than one sample, there is not necessarily any reason to think that the most accurate is the test done on the "largest" tumor specimen. Clinically, treatment will be based on any positive test - in other words, given the benefit and minimal toxicity of hormonal therapy, most patients will be given the "benefit of the doubt" and given hormonal therapy if any ER test is positive.
Note 3: The most recent interpretation guidelines for ER/PR do not allow for a borderline result. Therefore, code 030 will rarely be used. If 1% or greater cells stain positive, the test results are considered positive. If less tha 1% stain positive, the results are considered negative.
Note 4: If the patient is ER positive and node negative a multigene tests such as OncotypeDX may be performed in which case another ER/PR test will be done. Do not record the results of that test in this field. Record only the results of the test which made the patient eligible to be given the multigene test.

Code	Description
000	Test not done (test was not ordered and was not performed)
010	Positive/elevated
020	Negative/normal; within normal limits
030	Borderline; undetermined whether positive or negative
080	Ordered, but results not in chart
996	Ordered, results not interpretable
999	Unknown or no information Not documented in patient record

CS Site-Specific Factor 1
Estrogen Receptor Assay (ERA)